Back to top
more

Teleflex (TFX)

(Real Time Quote from BATS)

$124.03 USD

124.03
264,547

-1.77 (-1.41%)

Updated Sep 19, 2025 02:54 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (87 out of 245)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

CVS Health Banks on Aetna Prospects, Omnicare May Disappoint

by Zacks Equity Research

CVS Health's (CVS) Aetna integration synergies bode well for the stock.

Zacks Equity Research

Boston Scientific to Sell Bead Suit, Make Way for BTG Buyout

by Zacks Equity Research

The sale of oncology bead products by Boston Scientific (BSX) is expected to be among the last steps undertaken by the company to obtain Federal Trade Commission's approval for BTG buyout.

Zacks Equity Research

Here's Why CVS Health (CVS) Should Be in Your Portfolio

by Zacks Equity Research

Investors' trust continues to be high in CVS Health (CVS), thanks to strength in its PBM business.

Zacks Equity Research

Here's Why Chemed (CHE) Should Remain in Your Portfolio Now

by Zacks Equity Research

Investors' trust in Chemed (CHE) continues to be high, banking on its sturdy segmental performance.

Zacks Equity Research

Edwards Lifesciences Recalls Heart Device on Balloon Rupture

by Zacks Equity Research

Shares of Edwards Lifesciences (EW) decline post product recall news.

Zacks Equity Research

Teleflex (TFX) Shares Down on Respiratory Care Product Recall

by Zacks Equity Research

Teleflex (TFX) issued a statement saying consumers who own the tampered product should immediately discontinue use and return all affected products.

Zacks Equity Research

Hill-Rom (HRC) Gains on Product Launch, Prudent Buyouts

by Zacks Equity Research

The contribution from new products is substantial to bolster top-line growth during the first half of fiscal 2019 at Hill-Rom (HRC).

Zacks Equity Research

Here's Why You Should Hold GNC Holdings (GNC) Stock for Now

by Zacks Equity Research

GNC Holdings (GNC) continues to witness investors' confidence, courtesy of a few positive factors like strategic new partnerships.

Zacks Equity Research

Bruker (BRKR) Launches the MALDI Biotyper Sirius System

by Zacks Equity Research

The launch is a milestone for Bruker (BRKR) in assay research and clinical studies for fast antibiotic-resistance testing.

Zacks Equity Research

Teleflex (TFX) Hits New 52-Week High on Solid Growth Drivers

by Zacks Equity Research

Teleflex (TFX) gains from acquisition of NeoTract and Vascular Solutions.

Zacks Equity Research

Here's Why You Should Invest in Teleflex (TFX) Stock Now

by Zacks Equity Research

Teleflex (TFX) benefits from rising investors' confidence, courtesy of the NeoTract acquisition.

Zacks Equity Research

Teleflex (TFX) Down 2.4% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Teleflex (TFX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Teleflex (TFX) Q1 Earnings Top Estimates, Margins Decline

by Zacks Equity Research

Teleflex (TFX) reports robust improvement in revenues on balanced growth across all segments and geographies.

Zacks Equity Research

KLA-Tencor (KLAC) to Post Q3 Earnings: What's in the Cards?

by Zacks Equity Research

KLA-Tencor's (KLAC) fiscal third-quarter earnings are likely to benefit from solid product portfolio. However, memory weakness and intensifying competition may impact its results.

Zacks Equity Research

Teleflex (TFX) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Teleflex (TFX) delivered earnings and revenue surprises of 3.70% and 1.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

What's in Store for AmerisourceBergen (ABC) in Q2 Earnings?

by Zacks Equity Research

Better-than-expected performance at Pharmaceutical Distribution and World Courier and higher revenues might aid AmerisourceBergen (ABC) in Q2 earnings. However, stiff competition might be a dampener.

Zacks Equity Research

Will Strong Competition Hurt Fitbit's (FIT) Earnings in Q1?

by Zacks Equity Research

Fitbit's (FIT) focus on innovation, including new smartwatches, is likely to benefit first-quarter results. However, intensifying competition in the wearables market remains a major concern.

Zacks Equity Research

What's in the Cards for Expedia Group's (EXPE) Q1 Earnings?

by Zacks Equity Research

Strength across segments is likely to drive Expedia Group's (EXPE) first-quarter revenues.

Zacks Equity Research

Can Mass Cytometry Drive Fluidigm's (FLDM) Q1 Earnings?

by Zacks Equity Research

Better-than-expected performance at mass cytometry market and higher revenues is likely to aid Fluidigm's (FLDM) in Q1 earnings. However, sluggishness in microfluidics market remains a dampener.

Zacks Equity Research

DENTSPLY SIRONA (XRAY) Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Higher Consumable revenues, product innovation and focus on R&D likely to aid DENTSPLY SIRONA (XRAY) in Q1 earnings. However, contraction is gross margin might be a dampener.

Zacks Equity Research

Integer Holdings (ITGR) Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Better-than-expected performance at C&V and Cardiac & Neuromodulation product lines and higher revenues might aid Integer Holdings (ITGR) in Q1. But decline in non-medical sales might be a dampener.

Zacks Equity Research

Teleflex (TFX) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Teleflex (TFX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Thermo Fisher (TMO) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research

Strong analytical instruments business, product portfolio expansion and prudent growth strategy are likely to support Thermo Fisher (TMO) in Q1. However, forex might act as a dampener.

Zacks Equity Research

What's in Store for Align Technology (ALGN) in Q1 Earnings?

by Zacks Equity Research

Higher Invisalign case volume, solid show by Clear Aligner segment and anticipated sturdy growth at Scanner and Service business are likely to support Align Technology (ALGN) in Q1. However, operating expenses are likely to act as dampeners.

Zacks Equity Research

Why Is Teleflex (TFX) Up 9.6% Since Last Earnings Report?

by Zacks Equity Research

Teleflex (TFX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.